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Abstract Women have long strived to possess long,
thick, and dark eyelashes. Prominent eyes and eyelashes
are often considered a sign of beauty and can be associated
with increased levels of attractiveness, conﬁdence, and
well-being. Numerous options may improve the appear-
ance of eyelashes. Mascara aims to temporarily darken,
lengthen, and thicken eyelashes using a combination of
waxes, pigments, and resins. Artiﬁcial eyelashes can be
adhered either to the dermal margin or to individual eye-
lashes. Individuals may even use eyelash transplantations
to improve the appearance of their eyelashes. The unique
properties of eyelashes (e.g., relatively long telogen and
short anagen phases compared with scalp hairs, slow rate of
growth, and a lack of inﬂuence by androgens) may allow
for speciﬁc aesthetic interventions to improve the appear-
ance of natural eyelashes. Some over-the-counter (OTC)
products may contain prostaglandin analogs that can affect
eyelash growth, but neither the safety nor efﬁcacy of these
OTC cosmetics has been fully studied. Originally indicated
for the reduction of intraocular pressure, the synthetic
prostaglandin analog bimatoprost was recently approved
for the treatment of hypotrichosis of the eyelashes. In a
double-blinded, randomized, vehicle-controlled trial,
bimatoprost safely and effectively grew natural eyelashes,
making them longer, thicker, and darker. Bimatoprost was
generally safe and well tolerated and appears to provide an
additional option for individuals looking to improve the
appearance of their eyelashes.
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Introduction
Since ancient times, physical beauty has been considered
an advantageous and sought-after trait [1]. Although the
deﬁnition of beauty varies over time and from culture to
culture, the face and the eyes in particular are recognized as
important contributors to physical beauty [1, 2]. Beautiful
eyes are associated with social advantages [1]. Eyelashes
that are long and thick are considered a sign of beauty in
many cultures and often have a positive psychological
effect on women [3–6]. To enhance the overall prominence
of their eyelashes, women have employed a number of
techniques, some dating back millennia [7].
Presently, many women rely on makeup or over-the-
counter (OTC) cosmetics to enhance the appearance of
their eyelashes. As of 2005, the global cosmetics and toi-
letries market totaled $155 billion and color cosmetics
(e.g., eye makeup, facial makeup, lip products, and nail
products) comprised 15% of that market or approximately
$24 billion (Allergan, Inc., Irvine, CA, unpublished data).
Eye makeup, which includes eye shadow, eye liner, and
mascara, represents the fastest-growing category of color
cosmetics in the U.S., with a growth rate of more than 6%
in 2005. In the U.S. alone, the annual mascara market is
estimated at $1.1 billion (Allergan, Inc., unpublished data).
Mascara can provide women with increased eyelash vol-
ume, longer, darker lashes, and improved curl [7; Allergan,
Inc., unpublished data].
In addition to makeup, the effects of which are tempo-
rary and subject to smudging, women have several longer-
lasting and sometimes permanent options for improving the
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and eyelash transplants [8, 9]. Recently, the U.S. Food and
Drug Administration (FDA) approved the use of bimato-
prost ophthalmic solution 0.03% (Latisse
, Allergan Inc.,
Irvine, CA), a synthetic prostaglandin analog, to increase
the length, thickness, and darkness of eyelashes in people
with hypotrichosis of the eyelashes (i.e., inadequate or not
enough eyelashes) (Latisse package insert, Allergan, Inc.,
2008).
Anatomy and Physiology of Eyelashes
Beyond their aesthetic and social functions, eyelashes serve
a protective function by defending the eye against debris
and triggering the blink reﬂex [10–12]. People generally
have between 100 and 150 lashes emanating from each of
their upper eyelids [11, 12]. Lower eyelashes are half as
numerous as upper eyelashes [11]. Upper eyelashes are
arranged in two to three rows. Similar to scalp hair, eye-
lashes are considered terminal hairs, and as such are
coarser, longer, and more pigmented than other hair types
(i.e., vellus and intermediate) [13]. Eyelashes are wider
than scalp hairs and, unlike other hair types, do not typi-
cally lose pigmentation and become gray with age. Eye-
lashes are distinct from all other hairs on the body in that
they lack an accompanying arrector pili muscle, and, unlike
many other hairs, are not inﬂuenced by androgens [13, 14].
As is true for all hair follicles on the body, all eyelash
follicles are present at birth and their numbers do not
increase during life [13, 15]. The hair follicles of many
mammals exhibit synchronous hair cycles, but in humans
the hair cycle is asynchronous such that some hair follicles
are growing while others are dormant [13]. The hair cycle
for all hair types is divided into the phases of anagen,
catagen, and telogen, but the average length of the cycle
and the individual phases varies by body location.
Though variable, the normal eyelash cycle is estimated
to last from 5 to 11 months (Fig. 1a) (Latisse package
insert, Allergan, Inc., 2008, and unpublished data) [13, 16,
17]. The growth phase of eyelash follicles, anagen, lasts
approximately 1–2 months. During anagen, in addition to
growth, melanogenesis and the subsequent transfer of
pigment to the hair shaft also occurs [13]. The duration of
anagen crucially impacts hair length [10]. Anagen is a
period of rapid cell proliferation and differentiation [18].
Following anagen, eyelash follicles enter catagen, a tran-
sition phase, which lasts approximately 15 days and is the
time during which epithelial elements of the follicle
undergo apoptosis or programmed cell death [13]. The
longest phase of the normal eyelash cycle, telogen or the
resting phase, lasts approximately 4–9 months [13, 16, 17].
Throughout telogen, no signiﬁcant cell differentiation,
proliferation, or apoptosis occurs [18]. Expulsion of the
previous hair (i.e., exogen) takes place during the transition
between telogen and anagen [10, 14].
In contrast to eyelashes, scalp follicles have a much
longer cycle, lasting several years [14, 15]. Anagen alone
can last up to 6–7 years for scalp hairs [13–15]. Relative
differences in the lengths of the hair cycle phases of eye-
lashes and scalp hair result in approximately 50% of upper
eyelash follicles being in telogen at any given time com-
pared with only 5% to 15% of scalp follicles [13–16].
Furthermore, eyelashes are typically slow-growing hairs,
growing at a rate of approximately 0.15 mm/day [17]
compared with 0.3–0.4 mm/day for scalp hair [16–18]. The
unique properties of the eyelash cycle differentiate eye-
lashes from other body hairs and may cause drugs that
affect hair growth in one location to enhance eyelash
prominence.
Surgical/Procedural Options
Artiﬁcial eyelashes are synthetic or donated human eye-
lashes that give the visual appearance of longer eyelashes.
Strips of artiﬁcial lashes can easily be adhered to the upper
eyelid [8]. As intimated by the nickname ‘‘falsies,’’ such
Fig. 1 a Hair cycle of normal
eyelashes. b Potential
mechanisms of action of
bimatoprost ophthalmic solution
0.03% on the eyelash cycle [13,
16, 17] (Latisse package insert
and unpublished data, Allergan,
Inc.)
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123lashes may not result in a natural appearance. Alterna-
tively, single eyelash extensions can be attached to indi-
vidual eyelashes [8, 19]. The procedure requires an hour
and a half to complete and can cost as much as $500 [19].
Artiﬁcial eyelashes are typically held in place by methac-
rylate-based adhesives that can result in allergic contact
dermatitis [8]. Similarly, the solvent used to remove arti-
ﬁcial eyelashes can also cause an allergic reaction in some
individuals. Depending on the type of artiﬁcial lash and the
procedure used to adhere them, artiﬁcial eyelashes can
remain in place from several days to several weeks [8, 19].
Lash Extender (myoﬁbril-styled eyelash extensions applied
by the patient) is another option.
Successful eyelash transplantations have been reported
in the medical literature, although their use in the absence
of congenital eyelash defects or a need for reconstruction is
controversial [9]. Eyelash transplantations transfer hair
follicles from the scalp onto the margins of the eyelid.
Because these transplanted lashes retain the qualities of
scalp hair, patients must regularly trim and curl the
implanted lashes [9, 20]. Complications of eyelash trans-
plantation include pain, bleeding, thick scar formation,
numbness, eyelid ptosis, and blindness [9].
Prescription Options
Bimatoprost ophthalmic solution 0.03% is the only FDA-
approved product to safely and effectively enhance the
growth of a patient’s own eyelashes. Bimatoprost is a
synthetic prostamide, or prostaglandin ethanolamide, ana-
log approved in 2001 for the reduction of elevated intra-
ocular pressure in patients with open-angle glaucoma or
ocular hypertension (Lumigan package insert, Allergan,
Inc., 2006). In one clinical trial, when administered as an
eye drop for the treatment of glaucoma, eyelash growth
was noted in 42.6% of patients treated with bimatoprost
once daily for a year [21]. Although such growth was
recorded as an adverse event, the potential aesthetic ben-
eﬁts of eyelash growth were recognized and led to the
development and testing of bimatoprost as a product
designed to increase eyelash prominence. When prescribed
to enhance eyelash prominence, bimatoprost is accompa-
nied by sterile, single-use-per-eye applicators and should
be applied once daily to the skin of the upper eyelid margin
at the base of the eyelashes (Latisse package insert,
Allergan, Inc., 2008).
The safety and efﬁcacy of once-daily bimatoprost 0.03%
solution in increasing overall eyelash prominence follow-
ing dermal administration to the upper-eyelid margins was
evaluated in a recent multicenter, double-blinded, ran-
domized, vehicle-controlled, parallel study of 278 adult
patients [22]. Starting at 8 weeks of treatment, bimatoprost
was associated with signiﬁcantly greater increases in
overall eyelash prominence than vehicle as measured by at
least a one-grade increase on the four-grade Global Eyelash
Assessment (GEA) scale. These changes were sustained
throughout the remainder of the treatment period
(16 weeks) and, at week 16, 78.1% of subjects treated with
bimatoprost exhibited at least a one-grade increase from
baseline in GEA score compared with 18.4% of patients
treated with vehicle (P\0.0001) (Fig. 2). Improvements
in GEA scores continued to favor bimatoprost 4 weeks
after discontinuation of treatment (i.e., the post-treatment
visit at week 20). In the same study, efﬁcacy was assessed
by digital image analysis of superior-view eyelash photo-
graphs taken with standardized equipment and after uni-
form subject preparation at all visits. As assessed by such
analysis, at week 16 bimatoprost treatment was associated
with a mean 25% increase in eyelash length vs. 2% for
vehicle, a mean 106% increase in eyelash thickness vs.
12% for vehicle, and a mean 18% increase in eyelash
darkening vs. 3% for vehicle (Fig. 3). Subjects treated with
bimatoprost for eyelash growth also reported feeling sig-
niﬁcantly more satisﬁed with their eyelashes, more conﬁ-
dent in their looks, more attractive, more professional, and
more satisﬁed with their daily routine than those subjects
receiving vehicle as assessed by patient-reported outcome
questionnaires.
Fig. 2 Sample images of patient eyelashes before and after 16 weeks
of once-daily bimatoprost treatment. The patient entered the study
with a baseline overall eyelash prominence assessed as moderate
(grade 2) on the Global Eyelash Assessment (GEA) scale. After
16 weeks of double-blind treatment with bimatoprost ophthalmic
solution 0.03%, the patient’s eyelashes were markedly prominent
(i.e., GEA score of 3). In determining GEA scores, raters utilized a
photonumeric guide and evaluated overall eyelash prominence,
including length, fullness, and color of both upper eyelashes, with
length considered the most important feature
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ces eyelash growth has not been fully elucidated, it is
believed to increase the percentage of lash follicles in and
the duration of anagen (Fig. 1b) (Latisse package insert,
Allergan, Inc., 2008). Bimatoprost also appears capable of
stimulating melanogenesis [23], which likely explains the
changes in the pigmentation of eyelashes observed with
use. The duration of the effect of bimatoprost on eyelashes
is not fully known and has not been evaluated beyond
4 weeks post-treatment. Furthermore, the ability of
bimatoprost to affect the growth of eyelashes in patients
with systemic diseases or eyelash loss has not been
evaluated.
The safety of bimatoprost, applied either dermally or as
an eye drop, has been demonstrated in numerous trials [21,
24]. When applied as an eye drop (i.e., for the treatment of
ocular hypertension), bimatoprost was generally well tol-
erated with long-term use for up to 4 years [24]. Other than
eyelash growth, the most common adverse events reported
when bimatoprost is instilled into the eye include conjunc-
tival hyperemia, eye pruritus, eye dryness, a burning sen-
sation in the eye, eyelid pigmentation, foreign body
sensation,eyepain,andvisualdisturbance [21,24;Lumigan
package insert, Allergan, Inc., 2006]. Although rare,
bimatoprost when applied as an eye drop has also been
associated with increases in iris pigmentation, which are
generally thought to be permanent [25]; Lumigan package
insert,Allergan,Inc.,2006].Whileirispigmentationwasnot
seen in the controlled clinical studies with dermal applica-
tion for eyelash growth, there have been a small number of
post-marketing reports of iris pigmentation following use of
bimatoprost for eyelash growth (data on ﬁle, Allergan
Medical Affairs, June 2010). Post-marketing reports are
often incomplete and difﬁcult to evaluate on an individual
basis. However, to date there have been no identiﬁed trends
of risk factors reported in these small numbers of cases.
Patients should be advised of the small potential for
increased brown iris pigmentation which is likely to be
permanent. Infection following application is also a possi-
bility and should be limited by following the package insert
instructions for application with daily single-dose applica-
tors for each eye, which are provided with each package.
Although clinical experience regarding the safety of
bimatoprost 0.03% applied dermally is limited, available
data suggest that the safety proﬁle may be even more
favorable than that described above for intraocular
administration. In the pivotal trial, the most common
adverse events associated with bimatoprost use were eye
pruritus, conjunctival hyperemia, skin hyperpigmentation,
ocular irritation, dry eye symptoms, and erythema of the
eyelid, all occurring in fewer than 4% of patients (Latisse
package insert, Allergan, Inc., 2008). Conjunctival hyper-
emia was the only speciﬁc event reported at a signiﬁcantly
higher rate by subjects receiving bimatoprost (3.6%) than
those receiving vehicle (0%) (P = 0.03) [22]. For com-
parison, in a 3-month trial of once-daily bimatoprost
treatment for glaucoma or ocular hypertension (i.e., the
drug was instilled as an eye drop), the incidence of treat-
ment-related conjunctival hyperemia and eye pruritus was
approximately 46 and 9%, respectively [26]. Furthermore,
dermal application of bimatoprost was not associated with
iridal pigmentation or clinically meaningful changes in
intraocular pressure [22; Latisse package insert, Allergan,
Inc., 2008]. Differences in safety proﬁles of bimatoprost by
route of administration may be partially explained in that a
single application of bimatoprost 0.03% to the upper-eyelid
margin using the provided applicator delivers approxi-
mately 5% of the dose delivered for the treatment of
glaucoma (Allergan, Inc., unpublished data). Moreover,
when applied to the upper-eyelid margin, subsequent
absorption of the active drug into ocular tissues is expected
to be minimal due to the barrier function of the skin and the
small surface area to which the dose is applied.
The ability of prostaglandin analogs to increase eyelash
growth does not appear limited to bimatoprost. Published
reports describe latanoprost and travoprost, both prosta-
glandin analogs used to treat ocular hypertension, as being
associated with eyelash changes, including increases in
length and darkness [3, 5, 13, 27–29]. Studies evaluating
the clinical efﬁcacy of bimatoprost versus latanoprost for
the treatment of ocular hypertension suggest that the side
effect of increased eyelash growth is more common with
bimatoprost [28]. However, these results are not neces-
sarily comparable to those when these drugs are applied to
the upper-eyelid margin, which have not been evaluated in
any head-to-head studies. In addition, studies in which
Fig. 3 Changes in eyelash length, thickness, and darkness associated
with bimatoprost in a double-blind, vehicle-controlled trial [22].
Eyelash qualities were assessed by digital image analysis based on
superior-view digital eyelash photographs taken with standardized
equipment and subject preparation. Last observation carried forward
was performed on weeks 1–16. * P\0.0001 vs. placebo based on the
Wilcoxon rank-sum test
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typically fail to quantify the changes using objective
measures.
While other prostaglandin analogs appear capable of
inﬂuencing eyelash growth, these products are not FDA-
approved for the treatment of hypotrichosis. Their efﬁcacy
when applied to the upper-eyelid margins has not been
fully studied in clinical trials. Moreover, the safety of these
drugs when applied dermally has not been fully evaluated.
OTC Cosmetic Options
The Federal Food, Drug, and Cosmetic Act deﬁnes cos-
metics as ‘‘articles intended to be rubbed, poured, sprin-
kled, or sprayed on, introduced into, or otherwise applied to
the human body or any part thereof for cleansing, beauti-
fying, promoting attractiveness, or altering the appear-
ance’’ [30]. The FDA requires cosmetics to have an
ingredient declaration but cosmetic products and ingredi-
ents are not subject to FDA premarket approval [31]. A
product can be considered both a drug and a cosmetic by
the FDA if it has multiple uses [32].
Historically, mascara has been used to lengthen, thicken,
and darken eyelashes via the use of waxes, pigments, res-
ins, as well as talc or ﬁbers. In the case of liquid mascara,
these ingredients adhere to lashes after the product dries,
resulting in a temporary enhancement in the appearance of
a person’s eyelashes [7, 8]. A number of nonmascara OTC
cosmetic products are advertised to increase the length,
fullness, and/or darkness of eyelashes. These products
contain various ingredients such as ones described as
‘‘proprietary peptides’’ [33], natural extracts [34, 35],
vitamins [33], and prostaglandin analogs. Some of the
products that contain possible prostaglandin analogs include
MD Lash Factor [36], Revitalash [37], LiLash [38], neuLash
[39], Lashes to Die For [40], and RapidLash [41, 42].
As cosmetics, the efﬁcacy of the above OTC products
has not been critically evaluated and their safety has not
been fully studied. Most are applied to the skin of the
upper-eyelid margin and the mechanisms by which they
may affect eyelash growth are largely unknown and
unproven. These products also vary in the quality and
comprehensiveness of patient/consumer education regard-
ing proper use of the cosmetic.
In addition to the possibility of ingredient-speciﬁc safety
concerns, mascara and other cosmetic eyelash enhancers
carry a risk of bacterial and fungal contamination and
subsequent infection in addition to a risk of conjunctival
pigmentation [7]. Unlike prescription products, cosmetics
do not beneﬁt from a comprehensive pharmacovigilance
program to detect any safety concerns that become evident
with increased clinical use.
Conclusions
It is clear that eyelashes play an important role in deter-
mining beauty, and as such, prominent eyelashes are a
highly sought-after attribute. Numerous options may
improve the appearance of eyelashes, including mascara,
artiﬁcial eyelashes, eyelash transplantation, and prosta-
glandin analogs. Prostaglandin analogs appear capable of
inﬂuencing eyelash growth and are contained in several
OTC cosmetics. Eyelash growth has also been associated
with several prescription prostaglandin analogs used to
treat glaucoma and ocular hypertension. The FDA has
recently approved bimatoprost as the ﬁrst and only option
for the treatment of hypotrichosis of eyelashes [12]. In a
vehicle-controlled trial, bimatoprost resulted in increased
prominence, length, thickness, and darkness of patients’
natural eyelashes as assessed by clinician ratings and dig-
ital image analysis [27]. As an ocular antihypertensive
agent, bimatoprost has a proven history of safety, and when
applied dermally it was safe and well tolerated with a low
incidence of adverse events.
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